Skip to main content

Recent News

  • Jul 14, 2020
    psA.fil_.toes_.jpg
    A one year head-to-head (H2H) trial has shown ixekizumab (IXE) to be superior to adalimumab (ADA) in psoriatic arthritis (PsA); for both skin and articular outcomes. The SPIRIT H2H study was a 52-week trial of 566 biologic DMARD naive, PsA patients, randomized to received either IXE or ADA. The primary end point was at Wk 24, but the newly published data shows week 52 results for ACR50 and Psoriasis Area and Severity Index 100 responses. 
    Read Article

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

Jul 14, 2020

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article
NEW #COVID19—"Symmetric peripheral polyarthritis developed during #SARSCoV2 infection" Comment by Rosario Talarico and colleagues https://t.co/IqHp2GMLao #LancetRheumatology https://t.co/v3MBNDUnzG
The Lancet Rheumatology @TheLancetRheum (  View Tweet)
Jul 14, 2020
FDA has approved guselkumab (Tremfya) for active psoriatic arthritis, making it the 1st IL-23 inhibitor approved for PsA. Approval is based on DISCOVER-1 & DISCOVER-2 RCTs. Dosing: 100 mg SC q8 wks after loading dose at 0, 4 wks. https://t.co/1nCWuC1zii

Dr. John Cush @RheumNow (  View Tweet)

Jul 14, 2020
EMR analysis of 453 gout pts D/C from ED or hospital , shows that 28.3% received opioids at discharge (~80% new pts).

Dr. John Cush @RheumNow (  View Tweet)

Jul 14, 2020
Nice overview of Lupus Nephritis (III, IV, V) and biopsy results from the Renal Fellow Network https://t.co/tw1d5ldM04

Dr. John Cush @RheumNow (  View Tweet)

Jul 14, 2020

Growing Risk of COVID Among Adolescents

Jul 13, 2020

The risk COVID-19 infection and mortality in the U.S. has been closely correlated with increasing age. However, recent data suggests that young adults (aged 18–25 years) have shown an increasing risk of COVID-19 infection since the pandemic began in March 2020.

Read Article

Extrapulmonary Manifestations of COVID-19

Jul 13, 2020

A new article in Nature Medicine delineates how our understanding of COVID-19 infection has evolved over time, such that the infection outomes may be worsened by extrapulmonary manifestations; notably thrombotic, cardiac, renal, gastrointestinal hepatic, neurologic, and other complications.

Read Article
Who you gonna call? Fauci that's who. Listen to Fauci LTF! LTF!

Dr. John Cush @RheumNow (  View Tweet)

Jul 13, 2020
FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis.

Dr. John Cush @RheumNow (  View Tweet)

Jul 13, 2020
Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM
Dr. John Cush @RheumNow (  View Tweet)
Jul 13, 2020
SLE study from UK Clinical Practice registry matched 4343 SLE pts 1:6 controls; found lupus had 80% increased mortality risk (HR 1.8; CV, infx, Resp, accident/suicide). Higher risk w. younger onset & steroid.

Dr. John Cush @RheumNow (  View Tweet)

Jul 13, 2020
Reminders on Masking: 1. Everyone should wear masks; most who are infected dont know they are infx (asymptomatic); 2.

Dr. John Cush @RheumNow (  View Tweet)

Jul 13, 2020

ICYMI: Protective Benefit of Colchicine in COVID-19 Infection

Jul 10, 2020

Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had less clinical deterioration without significant changes in biomarkers, such as high-sensitivity cardiac troponin and C-reactive protein.

Read Article
10 FALSE reasons for not wearing a mask - https://t.co/zOViN8n4Yw Please wear a mask out of concern and care for others !!

Dr. John Cush @RheumNow (  View Tweet)

Jul 10, 2020
Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM
Dr. John Cush @RheumNow (  View Tweet)
Jul 10, 2020
Open label, uncontrolled study shows that background use of azathioprine (2mg/kg) in Pegloticase treated refractory… https://t.co/uXQR8JE1he

Dr. John Cush @RheumNow (  View Tweet)

Jul 10, 2020
Skin is often involved w/ ANCA+ vasculitis - 1184 AAV pt study shows skin involvement in 34% GPA; 28% MPA & 47% EGPA. Common are petechiae/purpura pruritus, urticaria, and maculopapular rash.

Dr. John Cush @RheumNow (  View Tweet)

Jul 10, 2020
Great NY Times article on 30+ years of an adversarial friendship between Dr. Tony Fauci and AIDS activist Larry Kramer (who recently passed away). Keen that adversaries can still be on the same side, pushing for change differently https://t.co/lnfk6fXfF2

Dr. John Cush @RheumNow (  View Tweet)

Jul 10, 2020
H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in P… https://t.co/7lwVCSYjPu

Dr. John Cush @RheumNow (  View Tweet)

Jul 09, 2020
Avacopan is as effective as steroids in ANCA Assoc Vasculitis – 330 pt RCT AAV Rx w/ RTX or CTX but randomized to p… https://t.co/mxm5NAjZtL

Dr. John Cush @RheumNow (  View Tweet)

Jul 09, 2020
×